$PEN
Penumbra Inc Stock $pen

$pen Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000132173223000088 Filed on August 01, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$270.9M	$261.5M
YoY Change	26.8%	25.51%
Cost Of Revenue	$93.23M	$94.64M
YoY Change	18.99%	27.36%
Gross Profit	$177.7M	$166.9M
YoY Change	31.32%	24.49%
Gross Profit Margin	65.59%	63.81%
Selling, General & Admin	$125.9M	$124.9M
YoY Change	15.98%	9.01%
% of Gross Profit	70.85%	74.88%
Research & Development	$20.96M	$21.54M
YoY Change	-1.7%	10.11%
% of Gross Profit	11.79%	12.91%
Depreciation & Amortization	$6.930M	$6.710M
YoY Change	11.33%	13.17%
% of Gross Profit	3.9%	4.02%
Operating Expenses	$165.1M	$149.0M
YoY Change	27.1%	11.03%
Operating Profit	$12.63M	$17.89M
YoY Change	132.33%	-12969.78%
Interest Expense	$1.123M	$839.0K
YoY Change	-2711.63%	-1265.28%
% of Operating Profit	8.9%	4.69%
Other Income/Expense, Net	-$444.0K	$808.0K
YoY Change	-81.15%	-184.52%
Pretax Income	$13.30M	$19.54M
YoY Change	338.35%	-1774.04%
Income Tax	$4.100M	$576.0K
% Of Pretax Income	30.82%	2.95%
Net Earnings	$9.214M	$18.96M
YoY Change	-505.72%	-614.24%
Net Earnings / Revenue	3.4%	7.25%
Basic Earnings Per Share	$0.24	$0.49
Diluted Earnings Per Share	$0.23	$0.48
COMMON SHARES
Basic Shares Outstanding	38.44M shares	38.25M shares
Diluted Shares Outstanding	39.22M shares	39.20M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$248.9M	$221.1M
YoY Change	34.93%	8.17%
Cash & Equivalents	$100.8M	$114.2M
Short-Term Investments	$148.1M	$106.9M
Other Short-Term Assets	$38.80M	$39.08M
YoY Change	29.82%	28.89%
Inventory	$374.2M	$358.8M
Prepaid Expenses
Receivables	$206.6M	$209.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$868.5M	$827.9M
YoY Change	20.02%	15.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.63M	$285.2M
YoY Change	2.42%	349.44%
Goodwill	$166.0M	$166.2M
YoY Change	0.32%	0.23%
Intangibles	$73.45M	$76.12M
YoY Change	-11.89%	-11.66%
Long-Term Investments
YoY Change
Other Assets	$14.74M	$77.17M
YoY Change	9.35%	452.41%
Total Long-Term Assets	$599.9M	$604.7M
YoY Change	0.32%	-0.87%
TOTAL ASSETS
Total Short-Term Assets	$868.5M	$827.9M
Total Long-Term Assets	$599.9M	$604.7M
Total Assets	$1.468B	$1.433B
YoY Change	11.11%	7.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.00M	$25.82M
YoY Change	10.37%	11.79%
Accrued Expenses	$104.2M	$107.9M
YoY Change	2.47%	-3.15%
Deferred Revenue	$8.274M	$8.430M
YoY Change	-14.98%	-15.35%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.100M	$1.984M
YoY Change	11.82%	9.86%
Total Short-Term Liabilities	$145.1M	$144.1M
YoY Change	4.88%	-1.02%
LONG-TERM LIABILITIES
Long-Term Debt	$23.80M	$23.92M
YoY Change	-6.02%	-6.75%
Other Long-Term Liabilities	$3.265M	$197.9M
YoY Change	-0.91%	5601.12%
Total Long-Term Liabilities	$3.265M	$221.9M
YoY Change	-0.91%	6290.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$145.1M	$144.1M
Total Long-Term Liabilities	$3.265M	$221.9M
Total Liabilities	$364.2M	$366.0M
YoY Change	4.71%	2.26%
SHAREHOLDERS EQUITY
Retained Earnings	$80.64M	$71.43M
YoY Change	101.46%	68.86%
Common Stock	$38.00K	$38.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.104B	$1.067B
YoY Change
Total Liabilities & Shareholders Equity	$1.468B	$1.433B
YoY Change	11.11%	7.88%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$9.214M	$18.96M
YoY Change	-505.72%	-614.24%
Depreciation, Depletion And Amortization	$6.930M	$6.710M
YoY Change	11.33%	13.17%
Cash From Operating Activities	$30.84M	$17.10M
YoY Change	-338.9%	-143.21%
INVESTING ACTIVITIES
Capital Expenditures	$3.330M	$4.342M
YoY Change	-152.46%	-197.99%
Acquisitions
YoY Change
Other Investing Activities	-$41.07M	-$2.329M
YoY Change	-354.56%	-109.28%
Cash From Investing Activities	-$44.40M	-$6.671M
YoY Change	-553.71%	-132.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	210.0K	8.694M
YoY Change	-134.83%	-4.79%
NET CHANGE
Cash From Operating Activities	30.84M	17.10M
Cash From Investing Activities	-44.40M	-6.671M
Cash From Financing Activities	210.0K	8.694M
Net Change In Cash	-13.35M	19.12M
YoY Change	258.29%	-295.44%
FREE CASH FLOW
Cash From Operating Activities	$30.84M	$17.10M
Capital Expenditures	$3.330M	$4.342M
Free Cash Flow	$27.51M	$12.76M
YoY Change	-519.3%	-136.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21537000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19559000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41523000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40123000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	148972000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	134174000	usd
	us-gaap	Operating Expenses OperatingExpenses	292036000	usd
	us-gaap	Operating Expenses OperatingExpenses	265638000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	17889000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-139000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	25897000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4185000	usd
CY2023Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	839000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-72000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1393000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-119000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	808000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-956000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	898000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1967000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	18960000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1103000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3466000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7998000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1900000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9022000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4186000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-3687000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	970015000	usd
	us-gaap	Profit Loss ProfitLoss	-3608000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11655000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17679000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1399000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2450000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3587000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8421000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25758000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5901000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-259000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1635000	usd
	pen	Increase Decrease In Lease Incentives IncreaseDecreaseInLeaseIncentives	0	usd
	pen	Increase Decrease In Lease Incentives IncreaseDecreaseInLeaseIncentives	230000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44089000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	15194000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1180000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	44579000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9388000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36371000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4568000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	7998000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5081000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	858000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-137000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6490000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1145000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58234000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	51191000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	89000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3059000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	8458000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2157000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Organization and Description of Business </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penumbra, Inc. (the “Company”) is a global healthcare company focused on innovative therapies. The Company designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. The Company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and other healthcare providers to drive improved clinical and health outcomes. The Company believes that the cost-effectiveness of our products is attractive to our customers.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and equity accounts; disclosure of contingent assets and liabilities at the date of the financial statements; and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to marketable investments, allowances for credit losses, the amount of variable consideration included in the transaction price, warranty reserve, valuation of inventories, useful lives of property and equipment, intangibles, operating and financing lease right-of-use (“ROU”) assets and liabilities, income taxes, contingent consideration and other contingencies, including the probability of achieving performance targets associated with equity awards with performance conditions, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which </span></div>form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other data. Actual results could differ from those estimates.
	pen	Numberof Business Activities NumberofBusinessActivities	1	activity
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	108907000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2012000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	106896000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	121672000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	118172000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	29173000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	160000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	73253000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1852000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	102426000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2012000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	19894000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	169000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	93658000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3331000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	113552000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3500000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	71589000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	70480000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	37318000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	36416000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	108907000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	106896000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	100167000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	90786000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	42391000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	26793000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	216212000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	216427000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	358770000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	334006000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	61945000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	60480000	usd
CY2023Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	10507000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	10902000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8430000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9158000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24724000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25760000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	105606000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	106300000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5370000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4310000	usd
	pen	Standardand Extended Product Warranty Accrual Increase Decreasefor Changesin Estimatefor Newand Preexisting Warranties StandardandExtendedProductWarrantyAccrualIncreaseDecreaseforChangesinEstimateforNewandPreexistingWarranties	1025000	usd
CY2022	pen	Standardand Extended Product Warranty Accrual Increase Decreasefor Changesin Estimatefor Newand Preexisting Warranties StandardandExtendedProductWarrantyAccrualIncreaseDecreaseforChangesinEstimateforNewandPreexistingWarranties	2451000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	645000	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1391000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5750000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5370000	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y8M12D
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	95034000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18918000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76116000	usd
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y7M6D
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	96574000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15413000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	81161000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2554000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2038000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5106000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4086000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	166046000	usd
	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	120000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	166166000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12823000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8786000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25589000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17679000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2100000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2200000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	600000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2500000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.029
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.159
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2700000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.024
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.425
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	18960000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27522000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3608000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38320999	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37767519	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38254042	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37707156	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	880156	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	897370	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39201155	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37767519	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39151412	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37707156	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1766000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1878000	shares
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	261499000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208344000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	502897000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	412239000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	261499000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208344000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	502897000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	412239000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7883000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8783000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	900000	usd
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true

Files In Submission

Name	View Source	Status
0001321732-23-000088-index-headers.html	Edgar Link	pending
0001321732-23-000088-index.html	Edgar Link	pending
0001321732-23-000088.txt	Edgar Link	pending
0001321732-23-000088-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pen-20230630.htm	Edgar Link	pending
pen-20230630.xsd	Edgar Link	pending
pen-63023xexhibit311.htm	Edgar Link	pending
pen-63023xexhibit312.htm	Edgar Link	pending
pen-63023xexhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pen-20230630_lab.xml	Edgar Link	unprocessable
pen-20230630_pre.xml	Edgar Link	unprocessable
pen-20230630_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pen-20230630_cal.xml	Edgar Link	unprocessable
pen-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PEN
Penumbra Inc Stock $pen

2023 Q3 Form 10-Q Financial Statement

#000132173223000088 Filed on August 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PEN Penumbra Inc Stock $pen

2023 Q3 Form 10-Q Financial Statement

#000132173223000088 Filed on August 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PEN
Penumbra Inc Stock $pen